SRR1418837
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.397
- PANCREAS_BETA_CELLS+0.371
- MYOGENESIS+0.315
- ESTROGEN_RESPONSE_EARLY+0.275
- SPERMATOGENESIS+0.269
- OXIDATIVE_PHOSPHORYLATION+0.252
- CHOLESTEROL_HOMEOSTASIS+0.227
- UV_RESPONSE_DN+0.216
- HEDGEHOG_SIGNALING+0.215
- ESTROGEN_RESPONSE_LATE+0.193
Top 10 suppressed
- MYC_TARGETS_V1-0.550
- E2F_TARGETS-0.487
- G2M_CHECKPOINT-0.469
- INTERFERON_ALPHA_RESPONSE-0.460
- MYC_TARGETS_V2-0.456
- ALLOGRAFT_REJECTION-0.438
- DNA_REPAIR-0.417
- INTERFERON_GAMMA_RESPONSE-0.369
- UNFOLDED_PROTEIN_RESPONSE-0.342
- PROTEIN_SECRETION-0.321
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1442571 | GTEX | — | 0.906 |
| 2 | SRR1475168 | GTEX | — | 0.904 |
| 3 | SRR1409305 | GTEX | — | 0.901 |
| 4 | SRR1405485 | GTEX | — | 0.900 |
| 5 | SRR1396595 | GTEX | — | 0.899 |
| 6 | SRR1457482 | GTEX | — | 0.891 |
| 7 | SRR1421351 | GTEX | — | 0.884 |
| 8 | SRR1320115 | GTEX | — | 0.880 |
| 9 | SRR1480365 | GTEX | — | 0.879 |
| 10 | SRR1320963 | GTEX | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.397 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.371 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.315 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.275 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.269 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.252 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.227 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.216 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.215 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.193 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.181 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.168 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.162 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.161 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.128 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.121 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.103 | Inavolisib | — uncovered |
| HYPOXIA | 0.099 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.098 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.053 | Inavolisib | — uncovered |